Agenus Inc - Asset Resilience Ratio
Agenus Inc (AGEN) has an Asset Resilience Ratio of 0.73% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2023)
This chart shows how Agenus Inc's Asset Resilience Ratio has changed over time. Check AGEN strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Agenus Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AGEN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.14 Million | 0.73% |
| Total Liquid Assets | $2.14 Million | 0.73% |
Asset Resilience Insights
- Limited Liquidity: Agenus Inc maintains only 0.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Agenus Inc Industry Peers by Asset Resilience Ratio
Compare Agenus Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Agenus Inc (2000–2023)
The table below shows the annual Asset Resilience Ratio data for Agenus Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.14% | $447.00K | $313.91 Million | -3.41pp |
| 2022-12-31 | 3.55% | $14.68 Million | $413.56 Million | +0.33pp |
| 2021-12-31 | 3.22% | $14.99 Million | $465.96 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $214.51 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $136.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $138.40 Million | -- |
| 2016-12-31 | 3.18% | $4.99 Million | $156.99 Million | -11.26pp |
| 2015-12-31 | 14.43% | $34.96 Million | $242.23 Million | -5.03pp |
| 2014-12-31 | 19.47% | $14.51 Million | $74.53 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $34.84 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $34.67 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.81 Million | -- |
| 2009-12-31 | 21.80% | $10.00 Million | $45.87 Million | +4.25pp |
| 2008-12-31 | 17.55% | $9.99 Million | $56.95 Million | +8.12pp |
| 2007-12-31 | 9.43% | $4.20 Million | $44.54 Million | -12.33pp |
| 2006-12-31 | 21.76% | $15.88 Million | $72.95 Million | -5.63pp |
| 2005-12-31 | 27.39% | $28.53 Million | $104.15 Million | -25.92pp |
| 2004-12-31 | 53.32% | $70.94 Million | $133.06 Million | +30.28pp |
| 2003-12-31 | 23.03% | $32.27 Million | $140.08 Million | -5.70pp |
| 2002-12-31 | 28.74% | $25.60 Million | $89.06 Million | +26.40pp |
| 2000-12-31 | 2.34% | $3.00 Million | $127.97 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more